- Home
- REPL
REPL
Replimune Group Inc.
as 11-21-2024 11:38am EST
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WOBURN |
| Market Cap: | 816.4M | IPO Year: | 2018 |
| Target Price: | $17.00 | AVG Volume (30 days): | 508.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.92 - $12.97 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 469.74% |
Stock Insider Trading Activity of Replimune Group Inc. (REPL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sarchi Christopher | REPL | Chief Commercial Officer | Nov 18 '24 | Sell | $10.78 | 5,207 | $56,131.46 | 87,045 |
Latest Replimune Group Inc. News
REPL Breaking Stock News: Dive into REPL Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
12 days ago
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
GlobeNewswire
13 days ago
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
22 days ago
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
GlobeNewswire
a month ago
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GuruFocus.com
a month ago
Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings
Simply Wall St.
2 months ago
Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 48% Below Their Intrinsic Value Estimate
GlobeNewswire
2 months ago
Replimune to Present at Two Upcoming Investor Conferences
Compare REPL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "REPL Replimune Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.